FUJIFILM Corporation announced today a $850m investment package to accelerate the growth of its core Bio CDMO subsidiary, FUJIFILM Diosynth Biotechnologies. The expansions will double cell culture production for recombinant vaccines in the United States. In the United Kingdom gene therapy production will be increased ten-fold, cell culture capacity will be tripled and microbial fermentation output at the existing 5,000L scale facility will be doubled. The United Kingdom cell culture expansion will also include cGMP capacity for continuous manufacturing. Source: Fujifilm press release 29/6/2021